Product InformationKit supplied with the following:Two (2) vials of 20uL each 1mg/mL BirA biotin-protein ligase (40ug total)Two (2) vials of 1.5mL each BiomixA (0.5M bicine buffer solution, pH 8.3)Two (2) vials of 1.5mL each BiomixB (100mM ATP, 100mM Mg(OAc)2, 500uM d-biotin)Two (2) vials of 1.5mL each additional BIO-200 (500uM d-biotin) The BirA biotin-protein ligase (EC 6.3.4.15) adds d-biotin covalently to biotin-acceptor peptides/proteins via an ATP intermediate (biotinyl 5"-adenylate) in a highly efficient and targeted manner. The downstream applications of enzymatically biotinylated proteins are varied, important and powerful. The well known biotin-avidin/streptavidin interaction is often exploited for affinity chromatography or protein immobilization on surfaces or substrates. Protein detection via anti-biotin antibodies or avidin/streptavidin-reporter enzyme conjugates (-HRP, -alkaline phosphatase) or fluorescent probes becomes possible. Multimeric forms of biotinylated MHC molecules are popular tools in immunobiology.When used in combination with our AviTag™ biotin-acceptor peptide amino acid sequence, biotinylation occurs at twice the rate of the natural E. coli BCCP substrate and as much as an order of magnitude or more over other Biotinylation of Peptide sequences. The AviTag™ sequence consequently requires less of the BirA enzyme and shorter incubation times to biotinylate to completion than do other sequences available. If protein instability or protease activities are a concern this may be important to downstream success.Our BirA enzyme is E. coli wild-type, encoded by the birA gene, and purified to greater than 99% purity by traditional methods. Other names for this enzyme include: biotin ligase; biotin operon repressor protein; birA; biotin holoenzyme synthetase; biotin-[acetyl-CoA carboxylase] synthetase; biotin-[acetyl-CoA-carboxylase] ligase; biotin-[acetyl-CoA carboxylase] synthetase; acetyl CoA holocarboxylase synthetase; acetyl CoA holocarboxylase synthetase; biotin:apocarboxylase ligase; biotin holoenzyme synthetase; HCS.

亲和生物科学公司是一家私营生物技术公司，是一家开创抗体寡核苷酸结合(AOC)的公司。™)AOCs结合了单克隆抗体的组织选择性和基于寡核苷酸的治疗方法的精确性，以克服寡核苷酸传递的障碍和疾病的目标遗传驱动因素。它们的AOC平台，演示了疾病相关RNA在细胞类型和组织中的调节，包括肌肉、心脏、肝脏、肿瘤和免疫细胞。专有的平台技术可以在单一抗体支架上传递多种治疗性寡核苷酸。AOCs具有类似于抗体的药物性质，并允许将寡核苷酸有效载荷传递到其他运载平台所不提供的非肝组织。AOC也有其独特之处，因为可以处理不可药物的目标。

它们正在推进一系列的治疗计划，重点是罕见的肌肉疾病和其他严重疾病。主要项目是开发治疗杜氏肌营养不良和肌营养不良患者的治疗方法。还与制药合作伙伴合作开展项目。并得到了经验丰富的团队和受人尊敬的生命科学投资者的支持。